Company: LIMN
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001410578-25-001746
Chunk: 97

Company: Liminatus Pharma, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 97
---
 response to a number of factors, including, among others, the following:

| ● | the Selling Securityholders generally purchased the securities being registered for resale hereunder at prices that are lower than the current market prices for such securities and, accordingly, may be or are incentivized to sell them under the registration statement of which this prospectus is a part (for example, the Sponsor purchased the founder at a price per share of $0.004); |

| ● | the Selling Securityholders may be incentivized to sell their securities even if the prevailing trading price of such securities is at or significantly below the IPO price, because the prices at which they acquired their shares may be lower than prevailing market prices and/or the prices at which public investors purchased our securities in the open market, and therefore such Selling Securityholders may generate positive rates of return on their investment that would not be available to public shareholders that acquired their securities at higher prices. For example, based on the closing price of our Common Stock of $6.47 per share as of July 23, 2025, the shares purchased by the Sponsor would experience a potential profit of up to approximately $6.466 per share with respect to sales of the Common Stock received in consideration of the founder shares; |

| ● | the realization of any of the risk factors presented in this prospectus; |

| ● | the concentration of the ownership of our shares by a limited number of affiliated stockholders may limit interest in our securities; |

| ● | limited “public float” with a small number of persons whose sales or lack of sales could result in positive or negative pricing pressure on the market price for the Common Stock; |

| ● | additions or departures of key personnel; |

| ● | loss of a strategic relationship; |

| ● | variations in operating results from the expectations of securities analysts or investors; |

| ● | announcements of new products or services by us or our competitors; |

| ● | announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; |

| ● | investor perception of our industry or prospects; |

| ● | insider selling or buying; |

60

| ● | investors entering into short sale contracts; |

| ● | regulatory developments affecting our industry; |

| ● | changes in our industry; |

| ● | competitive pricing pressures; |

| ● | our ability to obtain working capital financing; |

| ● | our ability to execute our business plan; |

| ● | operating results that fall below expectations; |

|